Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
Aprea Therapeutics (NASDAQ:APRE) had its price target lowered by analysts at Wedbush from $11.00 to $7.00. They now have an "outperform" rating on the stock.